复发性低级别浆液性卵巢癌的二次肿瘤细胞减灭术:系统评价与Meta分析
该系统评价共筛选5296项研究,最终纳入9项,其中2项进入Meta分析。结果显示,二次肿瘤细胞减灭术(SCS)结束时存在可见残留病灶会负向影响无进展生存(HR=3.51,95%CI=1.72-7.14),而无残留病灶则显著改善总生存(HR=0.4,95%CI=0.23-0.7)。作者认为完全性SCS及次之的满意SCS与复发性低级别浆液性卵巢癌(LGSC)患者PFS和OS改善相关。
要点
- SCS后可见残留病灶与PFS负相关(HR=3.51,95%CI=1.72-7.14)。
- SCS无残留病灶与OS显著改善相关(HR=0.4,95%CI=0.23-0.7)。
- 作者认为复发性LGSC患者应依据病灶分布和功能状态评估SCS的作用,与无铂间期无关。
核心结论
- 完全性SCS以及次之的满意SCS与复发性LGSC患者的PFS和OS改善相关。
- 作者认为对于复发性LGSC,SCS作为初始治疗策略可能优于全身化疗。
- 作者建议复发性LGSC患者应依据病灶分布和功能状态评估SCS的作用,与无铂间期无关。
- 作者指出需要前瞻性研究进一步探讨SCS在复发性LGSC患者中的作用。
研究设计与样本
- 系统评价与Meta分析,检索Medline ALL、Embase Classic+Embase、Cochrane对照试验中心注册库、Cochrane系统评价数据库和Web of Science。
- 共筛选5296项研究,350项进入全文审查,最终9项纳入系统评价,2项符合PFS和OS的Meta分析标准。
主要发现
- SCS结束时存在可见残留病灶对PFS有负面影响(HR=3.51,95%CI=1.72-7.14)。
- SCS无残留病灶显著改善复发性LGSC患者OS(HR=0.4,95%CI=0.23-0.7)。
- 弥漫性和广泛性病灶分布与生存呈负相关。
- SCS作为复发性LGSC初始治疗与化疗相比与更优生存相关。
- 在该队列中,较短的无铂间期与更差生存无关。
关键数值与推荐
- 可见残留病灶对PFS影响:HR=3.51,95%CI=1.72-7.14。
- 无残留病灶对OS影响:HR=0.4,95%CI=0.23-0.7。
临床怎么用
- 作者认为完全性SCS及次之的满意SCS与复发性LGSC患者PFS和OS改善相关。
- 作者认为SCS作为复发性疾病的初始治疗策略可能优于全身化疗。
- 作者建议复发性LGSC患者应依据病灶分布和功能状态评估SCS的作用,与无铂间期无关。
局限性
- 作者指出需要前瞻性研究进一步探讨SCS在复发性LGSC患者中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Low-grade serous ovarian cancer (LGSC) is a relatively chemo-resistant disease with limited effective treatment options for patients with recurrence. Secondary cytoreductive surgery (SCS) is commonly offered at recurrence, although any benefit this has on survival is not fully determined. This review evaluates the impact of SCS, including residual disease, on progression-free survival (PFS) and overall survival (OS) in recurrent LGSC. METHODS: A comprehensive search of Medline ALL, Embase Classic + Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science was conducted to obtain studies evaluating optimal or complete SCS versus suboptimal SCS and the amount of residual disease in recurrent LGSC. Meta-analysis was performed and PFS and OS outcomes were calculated. RESULTS: 1Of 5296 studies screened, 350 progressed to full-text review, with 9 ultimately selected for inclusion in the systematic review. Two studies met criteria for meta-analysis of PFS and of OS. The presence of visible residual disease at the conclusion of SCS negatively impacted PFS (HR = 3.51, 95% CI = 1.72-7.14), whereas SCS with no residual disease significantly improved OS (HR = 0.4, 95% CI = 0.23-0.7) in patients with recurrent LGSC. Diffuse and extensive disease distribution was inversely linked to survival. In addition, SCS as an initial treatment for recurrent LGSC was associated with superior survival in comparison to chemotherapy. A short platinum-free interval was not associated with worse survival in this cohort. CONCLUSIONS: Complete SCS, and to a lesser extent optimal SCS, are associated with improved PFS and OS in patients with recurrent LGSC. SCS may be a better initial treatment strategy than systemic chemotherapy for recurrent disease. Patients with recurrent LGSC should be evaluated for the role of SCS based on disease distribution and functional status, irrespective of the platinum-free interval. Prospective studies are needed to further study the role of SCS in patients with recurrent LGSC.
引用
- Goldberg RM, Kim SR, Fazelzad R, et al. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 2021. PMID: 34756470. doi:10.1016/j.ygyno.2021.10.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。